Alternatives to amyloid for Alzheimer's disease therapies—a symposium report

Author:

Cable Jennifer1,Holtzman David M.2,Hyman Bradley T.3,Tansey Malú Gámez4,Colonna Marco5,Kellis Manolis67,Brinton Roberta D.8,Albert Marilyn9,Wellington Cheryl L.10,Sisodia Sangram S.1112,Tanzi Rudolph E.13

Affiliation:

1. PhD Science Writer New York New York

2. Department of Neurology Washington University in St. Louis, St. Louis Missouri

3. Massachusetts General Hospital Harvard Medical School Boston Massachusetts

4. Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease University of Florida College of Medicine, McKnight Brain Institute Gainesville Florida

5. Department of Pathology and Immunology Washington University School of Medicine St. Louis Missouri

6. MIT Computer Science and Artificial Intelligence Laboratory Cambridge Massachusetts

7. Broad Institute of MIT and Harvard Cambridge Massachusetts

8. Departments of Pharmacology and Neurology, College of Medicine the University of Arizona Tucson Arizona

9. Department of Neurology Johns Hopkins University School of Medicine Baltimore Maryland

10. Department of Pathology and Laboratory Medicine, Djavad Mowafaghian Centre for Brain Health, International Collaboration on Repair Discoveries, School of Biomedical Engineering University of British Columbia Vancouver British Columbia Canada

11. Department of Neurobiology the University of Chicago Chicago Illinois

12. The Microbiome Center the University of Chicago Chicago Illinois

13. Department of Neurology, Massachusetts General Hospital Harvard Medical School Boston Massachusetts

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Reference95 articles.

1. Epidemiology of Alzheimer Disease

2. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

3. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

4. Biogen & Eisai Co. Ltd.2019.Biogen plans regulatory filing for aducanumab in Alzheimer's disease based on new analysis of larger dataset from phase 3 studies. October 22 2019 Accessed January 5 2020.http://investors.biogen.com/news-releases/news-release-details/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease.

5. International Alzheimer's and Related Dementias Research Portfolio (IADRP).The A3 study: ante‐amyloid prevention of Alzheimer's disease.Accessed December 27 2019.https://iadrp.nia.nih.gov/project/a3-study-ante-amyloid-prevention-alzheimers-disease.

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3